We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

19 hedge funds and large institutions have $859K invested in Decoy Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

27% more funds holding

Funds holding: 15 → 19 (+4)

0% less ownership

Funds ownership: 0% → 0% (-0%)

41% less capital invested

Capital invested by funds: $1.45M → $859K (-$591K)

Holders
19
Holders Change
+4
Holders Change %
+26.67%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$112K
2
Millennium Management
Millennium Management
New York
+$60.4K
3
Citadel Advisors
Citadel Advisors
Florida
+$43.1K
4
TRCT
Tower Research Capital (TRC)
New York
+$17.3K
5
EFL
ERn Financial LLC
Wisconsin
+$8.63K

Top Sellers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
-$218K
2
BlackRock
BlackRock
New York
-$25.9K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$8.63K
4
XSC
X-Square Capital
Puerto Rico
-$8.63K
5
SRC
Shufro Rose & Co
New York
-$7K

DCOY Hedge Fund Activity: Q2 2022 in Review

19 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2022, worth a combined $859K — down 41% from $1.45M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new DCOY positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $112K. The largest seller was Kepos Capital, exiting entirely with an estimated $218K sold.

  • 19 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2022, up from 15 in Q1 2022.
  • Funds reported $859K of Decoy Therapeutics stock for Q2 2022, down 41% quarter-over-quarter.
  • 6 funds opened new Decoy Therapeutics positions in Q2 2022 and 2 closed out, a net change of +4 holders.
  • The largest Decoy Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $112K added.
  • The largest Decoy Therapeutics seller in Q2 2022 was Kepos Capital, an estimated $218K sold.

Based on aggregated 13F filings for Q2 2022.